What is OncoOne?
OncoOne is dedicated to enhancing patient outcomes and quality of life through the development of innovative precision cancer therapies. The company leverages two proprietary platform technologies, Anti-oxMIF and PreTarg-it, to engineer targeted therapies designed to address critical unmet needs within the oncology sector. Their unique approach integrates targeted antibodies with radiotherapy, aiming for more effective treatment of challenging cancers. This focus positions OncoOne at the forefront of personalized medicine in cancer care.
How much funding has OncoOne raised?
OncoOne has raised a total of $14.1M across 1 funding round:
Series A
$14.1M
Series A (2020): $14.1M, investors not publicly disclosed
What's next for OncoOne?
With a substantial enterprise-level funding context, OncoOne is poised for accelerated clinical development and potential market expansion. The recent major strategic investment likely signifies confidence from backers in the company's technology platforms and therapeutic pipeline. Future endeavors will probably involve forging strategic partnerships and securing further investment to advance its precision medicines through clinical trials and towards commercialization. The company's commitment to targeted therapies suggests a strategic focus on niche but high-impact areas within oncology.
See full OncoOne company page
